Solid Biosciences Inc.

/Solid Biosciences Inc.


Solid Biosciences Inc.

Their mission is to cure Duchenne muscular dystrophy, or DMD, a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age.



Final Price

Anticipated Shares

Effective Date
January 26, 2018

J.P. Morgan, Goldman Sachs & Co., Leerink Partners

To view the prospectus for Solid Biosciences Inc. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange